Cargando…
Vaccine immunotherapy with ARNAX induces tumor‐specific memory T cells and durable anti‐tumor immunity in mouse models
Immunological checkpoint blockade therapies benefit a limited population of cancer patients. We have previously shown that vaccine immunotherapy with Toll‐like receptor (TLR)3‐adjuvant and tumor antigen overcomes anti‐programmed death ligand‐1 (PD‐L1) resistance in mouse tumor models. In the present...
Autores principales: | Takeda, Yohei, Yoshida, Sumito, Takashima, Ken, Ishii‐Mugikura, Noriko, Shime, Hiroaki, Seya, Tsukasa, Matsumoto, Misako |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6029830/ https://www.ncbi.nlm.nih.gov/pubmed/29791768 http://dx.doi.org/10.1111/cas.13649 |
Ejemplares similares
-
Anti-oxidative Amino Acid L-ergothioneine Modulates the Tumor Microenvironment to Facilitate Adjuvant Vaccine Immunotherapy
por: Yoshida, Sumito, et al.
Publicado: (2019) -
Toll-like receptor 2 ligand and interferon-γ suppress anti-tumor T cell responses by enhancing the immunosuppressive activity of monocytic myeloid-derived suppressor cells
por: Shime, Hiroaki, et al.
Publicado: (2017) -
Adjuvant immunotherapy for cancer: both dendritic cell-priming and check-point inhibitor blockade are required for immunotherapy
por: SEYA, Tsukasa, et al.
Publicado: (2018) -
Toll‐like receptor 3 signal augments radiation‐induced tumor growth retardation in a murine model
por: Yoshida, Sumito, et al.
Publicado: (2018) -
Adjuvant for vaccine immunotherapy of cancer – focusing on Toll‐like receptor 2 and 3 agonists for safely enhancing antitumor immunity
por: Seya, Tsukasa, et al.
Publicado: (2015)